Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Head and Neck Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Head and Neck Neoplasm

Cancer Family

Head and Neck Neoplasm

CI-CAN-00000021Explore in graph →

Non-malignant1,571 active trials17 approved drugs142 evidence items

NCIt: C3077
MeSH: D006258

Overview
Statistics
Survival
Genomics28
Variants & evidence142
Drugs54
Trials6372
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (323)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 276–300 of 323 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
· Head Neck Oncol · 2010 · PMID 20504363 · validated civic_curation pubmed
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.
· Oncologist · 2019 · PMID 31391294 · validated civic_curation pubmed
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
· Cancer Res · 2013 · PMID 23786770 · validated civic_curation pubmed
Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma.
· Cold Spring Harb Mol Case Stud · 2018 · PMID 29610391 · validated civic_curation pubmed
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.
· JCO Precis Oncol · 2022 · PMID 35005993 · validated civic_curation pubmed
An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.
· Eur J Endocrinol · 2022 · PMID 35118995 · validated civic_curation pubmed
Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
· Mod Pathol · 2020 · PMID 32457407 · validated civic_curation

Showing 276–300 of 323 publications

← Previous
1
…
11
12
13
Next →

Morphologic and Ancillary Studies of Pediatric Acinic Cell Carcinoma: A Single Institute Experience.

· Head Neck Pathol · 2023 · PMID 36169793 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

· Clin Cancer Res · 2016 · PMID 26787751 · validated civic_curation pubmed

MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

· J Clin Endocrinol Metab · 2015 · PMID 25625803 · validated civic_curation pubmed

Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.

· Ann Otol Rhinol Laryngol · 2017 · PMID 28061634 · validated civic_curation pubmed

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature.

· Avicenna J Med · 2012 · PMID 23826550 · validated civic_curation pubmed

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.

· Oncotarget · 2018 · PMID 29515777 · validated civic_curation pubmed

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.

· Mod Pathol · 2020 · PMID 31375766 · validated civic_curation pubmed

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

· Cancer Cell · 2011 · PMID 21840482 · validated civic_curation pubmed

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

· Cancer Discov · 2015 · PMID 26359368 · validated civic_curation pubmed

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

· J Endocrinol Invest · 2012 · PMID 21422803 · validated civic_curation pubmed

AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.

· PLoS One · 2012 · PMID 23056499 · validated civic_curation pubmed

Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.

· Cancer Biol Ther · 2015 · PMID 26046389 · validated civic_curation pubmed

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.

· Clin Cancer Res · 2015 · PMID 26015511 · validated civic_curation pubmed

Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.

· PLoS One · 2015 · PMID 26267899 · validated civic_curation pubmed

Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.

· J Oral Pathol Med · 2016 · PMID 25677871 · validated civic_curation pubmed

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

· Cancer Discov · 2013 · PMID 23619167 · validated civic_curation pubmed

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

· Clin Cancer Res · 2016 · PMID 26589432 · validated civic_curation pubmed